Related Experiment Video

Updated: Mar 21, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K

Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition

Jan A Burger1, Dan A Landau2,3,4,5, Amaro Taylor-Weiner2

  • 1Department of Leukemia, MD Anderson Cancer Center, Houston, Texas 77030, USA.

Nature Communications
|May 21, 2016
PubMed

Insights

Ibrutinib resistance in chronic lymphocytic leukemia can arise from genetic mutations or chromosomal deletions, including del(8p). This therapy selects for pre-existing resistant subclones, revealing diverse resistance mechanisms beyond BTK mutations.

Area of Science:

  • Oncology
  • Hematology
  • Genetics

Background:

  • Resistance to Bruton's tyrosine kinase (BTK) inhibitors like ibrutinib in chronic lymphocytic leukemia (CLL) was previously thought to be solely due to mutations in BTK or related pathways.
  • Understanding the evolutionary mechanisms of ibrutinib resistance is crucial for improving treatment strategies in CLL.

Observation:

  • Serial samples from five CLL patients treated with ibrutinib were analyzed using whole-exome and deep-targeted sequencing.
  • Two patients developed known resistance mutations (BTK-C481S or PLCG2 mutations).
  • Three patients showed expansion of clones with del(8p) and other driver mutations, with one case progressing to CD19-negative histiocytic sarcoma.

Findings:

  • Droplet-microfluidic technology and growth kinetic analyses identified and quantified ibrutinib-resistant subclones present before treatment.
  • Haploinsufficiency of TRAIL-R due to del(8p) led to TRAIL insensitivity, potentially contributing to resistance.
  • Ibrutinib therapy selects for and expands rare, pre-existing subclones, highlighting genetic heterogeneity in resistance.

Implications:

  • The study reveals that ibrutinib resistance is not solely mutation-driven but can involve chromosomal abnormalities and pre-existing subclones.
  • These findings underscore the importance of assessing clonal heterogeneity before initiating ibrutinib therapy.
  • Insights into diverse resistance mechanisms can guide the development of more effective therapeutic approaches for CLL.

More Related Videos

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.7K
VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

27.4K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
17.1K
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
9.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K